Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical leader focused on pioneering therapies for immuno-inflammatory and dermatologic diseases. This page serves as the definitive source for verified news and press releases related to ACRS's research advancements, strategic partnerships, and operational developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and financial announcements. The curated collection includes updates on novel drug candidates like kinase inhibitors and antibody therapies targeting conditions with significant unmet medical needs.
All content is organized to provide clear insights into ACRS's dual-segment operations – from therapeutic innovations to contract research services. Regular updates ensure stakeholders stay informed about licensing agreements, pipeline expansions, and scientific breakthroughs without promotional bias.
Bookmark this page for streamlined access to essential Aclaris Therapeutics updates. Check back frequently for authoritative reporting on developments impacting both clinical research and investment considerations in the biopharmaceutical sector.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has been added to both the Russell 2000® and Russell 3000® Indexes following the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025.
The inclusion comes as part of FTSE Russell's annual reconstitution process, which ranks the 4,000 largest US stocks by market capitalization. Notably, approximately $10.6 trillion in assets are benchmarked against Russell US indexes as of June 2024. Membership in these indexes will remain in place for one year.
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, will deliver a corporate presentation at the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation is scheduled for Monday, June 30, 2025 at 11:30 AM EDT.
Investors and interested parties can access both the live and archived versions of the presentation through the Events page on the company's website, where it will remain available for a minimum of 30 days.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, has announced its participation in two major healthcare conferences in June 2025. The company's CEO Dr. Neal Walker and senior leadership team will participate in:
1. A fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2025, at 10:30 AM EDT
2. A fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami on June 11, 2025, at 1:20 PM EDT
Live webcasts of both events will be available on the Events page of Aclaris' website and will remain accessible for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has announced its participation in the HC Wainwright "HCW@Home" virtual series. The company's CEO Neal Walker and senior leadership team will engage in a fireside chat scheduled for May 16, 2025, at 1:00 PM EDT. Investors and interested parties can access the live webcast and a 30-day replay through the Events page on the company's website at aclaristx.com.
Aclaris Therapeutics has appointed Jesse Hall, M.D. as Chief Medical Officer, strengthening its leadership in immuno-inflammatory disease therapeutics. Dr. Hall brings extensive experience in clinical development, particularly in immunology and antibody development.
Dr. Hall's previous role was CMO at AltruBio, and he has held positions at notable companies including Sublimity Therapeutics, Ardea Biosciences (AstraZeneca), Amgen, and Abbott Labs. His track record includes work on successful monoclonal antibodies like HUMIRA and PROLIA.
As part of his employment package starting May 1, 2025, Dr. Hall will receive:
- 510,000 nonstatutory stock options
- 145,500 restricted stock units
These equity awards will vest over four years, with 25% vesting annually, subject to continued employment. The grants are part of Aclaris' 2024 Inducement Plan, designed for new employees under Nasdaq Rule 5635(c)(4).
Aclaris Therapeutics (NASDAQ: ACRS) has received FDA clearance for its Investigational New Drug (IND) application to conduct a Phase 1a/1b clinical trial of ATI-052, a bispecific anti-TSLP/IL-4R monoclonal antibody. The trial, expected to begin in Q2 2025, will evaluate single and multiple ascending doses followed by a proof-of-concept portion in an undisclosed indication.
ATI-052, acquired through a license agreement with Biosion, is designed to exhibit high binding affinity and dual blockade of both the TSLP ligand and IL-4 receptor, inhibiting key proinflammatory pathways. This bispecific antibody technology represents a potential advancement in immunotherapy, as these engineered antibodies can bind to two targets simultaneously, potentially offering enhanced efficacy over traditional monoclonal antibodies.
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, has announced its participation in two major healthcare conferences this March.
The company's leadership team, led by CEO Dr. Neal Walker, will engage in:
- A fireside chat at the Leerink Partners Global Healthcare Conference in Miami, Florida on March 11, 2025, at 3:00 PM EDT
- A virtual fireside chat during the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025, at 9:00 AM EDT
Both events will be webcast live and archived on the Events page of Aclaris' website, remaining accessible for at least 30 days following the presentations.